641615-35-2

Upstream product

• 641615-34-1 1-(5-pyrimidyl)-3-(dimethylamino)-2-propene-1-one 
• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 
• 99-55-8 2-methyl-5-nitroaniline 
• 1025717-41-2 2-(2-methyl-5-nitrophenylamino)pyrimidin-4-one 
• 109299-78-7 pyrimidine 5-boronic acid 
• 10325-70-9 1-(pyrimidin-5-yl)ethan-1-one 
• 1232062-67-7 (E)-3-(dimethylamino)-1-(pyrimidin-5-yl)prop-2-en-1-one 
• 152460-08-7 1-(2-methyl-5-nitrophenyl)guanidine nitrate 

Downstream Products

• 1232061-97-0 N-[3-(4,5'-bipyrimdine-2-ylamino)-4-methylphenyl]-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indene-5-carboxamide 
• 641615-36-3 N₁-([4,5'-bipyrimidin]-2-yl)-6-methylbenzene-1,3-diamine 

Relevant academic research and scientific papers

INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS

4-Oxo-2-phenylaminopyrimidine derivatives as intermediates for synth of tyrosine kinase inhibitors, in particular imatinib and nilotinib.

PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS THEIR PHARMACEUTICAL COMPOSITIONS CONTAING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR

The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR,

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

AMIDE DERIVATIVE

The present invention provides an amide derivative represented by the following general formula (1): wherein R1 represents a saturated cyclic amino group, R2 represents alkyl, halogen or haloalkyl, R3 represents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.